Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

345 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation.
Canu V, Donzelli S, Sacconi A, Lo Sardo F, Pulito C, Bossel N, Di Benedetto A, Muti P, Botti C, Domany E, Bicciato S, Strano S, Yarden Y, Blandino G. Canu V, et al. Among authors: botti c. Cell Death Differ. 2021 May;28(5):1493-1511. doi: 10.1038/s41418-020-00677-9. Epub 2020 Nov 23. Cell Death Differ. 2021. PMID: 33230261 Free PMC article.
The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors.
Di Modugno F, Mottolese M, Di Benedetto A, Conidi A, Novelli F, Perracchio L, Venturo I, Botti C, Jager E, Santoni A, Natali PG, Nisticò P. Di Modugno F, et al. Among authors: botti c. Clin Cancer Res. 2006 Mar 1;12(5):1470-8. doi: 10.1158/1078-0432.CCR-05-2027. Clin Cancer Res. 2006. PMID: 16533770 Free article.
Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.
Fabi A, Merola R, Ferretti G, Di Benedetto A, Antoniani B, Ercolani C, Nisticò C, Papaldo P, Ciccarese M, Sperduti I, Vici P, Marino M, Gori S, Botti C, Malaguti P, Cognetti F, Mottolese M. Fabi A, et al. Among authors: botti c. Expert Opin Pharmacother. 2013 Apr;14(6):699-706. doi: 10.1517/14656566.2013.779672. Epub 2013 Mar 9. Expert Opin Pharmacother. 2013. PMID: 23472669
p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab.
Vici P, Sperati F, Maugeri-Saccà M, Melucci E, Di Benedetto A, Di Lauro L, Pizzuti L, Sergi D, Terrenato I, Esposito L, Iannuzzi CA, Pasquale R, Botti C, Fuhrman B, Giordano A, Mottolese M, Barba M. Vici P, et al. Among authors: botti c. Oncotarget. 2014 Nov 15;5(21):10382-92. doi: 10.18632/oncotarget.2060. Oncotarget. 2014. PMID: 25071015 Free PMC article.
Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis.
Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, Sperati F, Terrenato I, Dattilo R, Botti C, Fabi A, Ramieri MT, Mentuccia L, Marinelli C, Iezzi L, Gamucci T, Natoli C, Vitale I, Barba M, Mottolese M, De Maria R, Maugeri-Saccà M. Vici P, et al. Among authors: botti c. Oncotarget. 2015 Dec 15;6(40):42773-80. doi: 10.18632/oncotarget.6001. Oncotarget. 2015. PMID: 26544894 Free PMC article.
Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy.
Vici P, Ercolani C, Di Benedetto A, Pizzuti L, Di Lauro L, Sperati F, Terrenato I, Gamucci T, Natoli C, Di Filippo F, Botti C, Barba M, Mottolese M, De Maria R, Maugeri-Saccà M. Vici P, et al. Among authors: botti c. J Exp Clin Cancer Res. 2016 Apr 2;35:62. doi: 10.1186/s13046-016-0338-7. J Exp Clin Cancer Res. 2016. PMID: 27039292 Free PMC article.
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial.
Pizzuti L, Barba M, Giannarelli D, Sergi D, Botti C, Marchetti P, Anzà M, Maugeri-Saccà M, Natoli C, Di Filippo S, Catenaro T, Tomao F, Amodio A, Carpano S, Perracchio L, Mottolese M, Di Lauro L, Sanguineti G, Di Benedetto A, Giordano A, Vici P. Pizzuti L, et al. Among authors: botti c. J Cell Physiol. 2016 Nov;231(11):2541-7. doi: 10.1002/jcp.25432. Epub 2016 Jun 2. J Cell Physiol. 2016. PMID: 27187274 Free PMC article. Clinical Trial.
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer.
Barba M, Vici P, Pizzuti L, Di Lauro L, Sergi D, Di Benedetto A, Ercolani C, Sperati F, Terrenato I, Botti C, Mentuccia L, Iezzi L, Gamucci T, Natoli C, Vitale I, Mottolese M, De Maria R, Maugeri-Saccà M. Barba M, et al. Among authors: botti c. BMC Cancer. 2017 Feb 6;17(1):101. doi: 10.1186/s12885-016-3045-z. BMC Cancer. 2017. PMID: 28166748 Free PMC article.
Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting.
Mandoj C, Pizzuti L, Sergi D, Sperduti I, Mazzotta M, Di Lauro L, Amodio A, Carpano S, Di Benedetto A, Botti C, Ferranti F, Antenucci A, D'Alessandro MG, Marchetti P, Tomao S, Sanguineti G, Giordano A, Maugeri-Saccà M, Ciliberto G, Conti L, Vici P, Barba M. Mandoj C, et al. Among authors: botti c. J Transl Med. 2018 May 16;16(1):129. doi: 10.1186/s12967-018-1511-x. J Transl Med. 2018. PMID: 29769125 Free PMC article.
p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study.
Fabi A, Mottolese M, Di Benedetto A, Sperati F, Ercolani C, Buglioni S, Nisticò C, Ferretti G, Vici P, Perracchio L, Malaguti P, Russillo M, Botti C, Pescarmona E, Cognetti F, Terrenato I. Fabi A, et al. Among authors: botti c. Clin Breast Cancer. 2020 Dec;20(6):e761-e770. doi: 10.1016/j.clbc.2020.05.005. Epub 2020 May 13. Clin Breast Cancer. 2020. PMID: 32580907
345 results